HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ulrike Stampfl Selected Research

poly(bis(trifluoroethoxy)phosphazene)

11/2008Reduction of late in-stent stenosis in a porcine coronary artery model by cobalt chromium stents with a nanocoat of polyphosphazene (Polyzene-F).
9/2008Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F nanocoated cobalt-chromium stents in the minipig coronary artery model.
7/2008Biocompatibility and recanalization characteristics of hydrogel microspheres with polyzene-F as polymer coating.
3/2008Efficacy of a polyphosphazene nanocoat in reducing thrombogenicity, in-stent stenosis, and inflammatory response in porcine renal and iliac artery stents.
5/2007The efficacy of nanoscale poly[bis(trifluoroethoxy) phosphazene] (PTFEP) coatings in reducing thrombogenicity and late in-stent stenosis in a porcine coronary artery model.
4/2005A new polymer concept for coating of vascular stents using PTFEP (poly(bis(trifluoroethoxy)phosphazene) to reduce thrombogenicity and late in-stent stenosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ulrike Stampfl Research Topics

Disease

8Pathologic Constriction (Stenosis)
03/2015 - 04/2005
8Inflammation (Inflammations)
08/2010 - 05/2007
4Thrombosis (Thrombus)
09/2008 - 04/2005
3Hemorrhage
12/2014 - 03/2012
2Neointima
11/2008 - 04/2005
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2015
1Superior Vena Cava Syndrome (Superior Vena Cava Obstruction)
03/2015
1Hematoma
12/2014
1Hepatocellular Carcinoma (Hepatoma)
07/2014
1False Aneurysm (Pseudoaneurysm)
03/2012
1Hypertrophy
01/2012
1Neoplasms (Cancer)
01/2012
1Wound Infection (Wound Infections)
12/2008
1Wounds and Injuries (Trauma)
12/2008
1Rupture
12/2008
1Pleural Empyema (Pyothorax)
12/2008

Drug/Important Bio-Agent (IBA)

6poly(bis(trifluoroethoxy)phosphazene)IBA
11/2008 - 04/2005
3PolymersIBA
11/2008 - 04/2005
2nitinolIBA
03/2015 - 07/2009
2Paclitaxel (Taxol)FDA LinkGeneric
08/2010 - 12/2009
2Transforming Growth Factor beta (TGF-beta)IBA
11/2008 - 09/2008
2poly(phosphazene)IBA
11/2008 - 03/2008
2CobaltIBA
11/2008 - 09/2008
2ChromiumIBA
11/2008 - 09/2008
2C-Reactive ProteinIBA
11/2008 - 09/2008
1Ethiodized Oil (Ethiodol)FDA Link
01/2012
1EnbucrilateIBA
01/2012
1Phenobarbital (Luminal)FDA Link
12/2009
1Pharmaceutical PreparationsIBA
12/2009
1Stainless Steel (Steel, Stainless)IBA
11/2008
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2008
1MetalsIBA
03/2008

Therapy/Procedure

10Stents
03/2015 - 04/2005
3Emergency Treatment
12/2014 - 03/2012
1Therapeutic Embolization
12/2014
1Therapeutics
10/2014
1Liver Transplantation
07/2014
1Hepatectomy
01/2012
1Coronary Artery Bypass (Coronary Artery Bypass Surgery)
12/2008
1Thoracotomy
12/2008
1Debridement
12/2008
1Drug-Eluting Stents
09/2008
1Microspheres (Microsphere)
04/2008